ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
ArriVent announced its pivotal Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC did not meet the primary endpoint of PFS by blinded independent central review. In the 398-patient trial, median PFS by BICR was 11.0 months for the 240mg arm versus 9.5 months for chemotherapy control (HR 0.75, p=0.0654), while secondary endpoints showed benefit: confirmed ORR of 60% versus 33% and investigator-assessed PFS favored both doses, with an immature trend toward overall survival improvement. The safety profile was consistent with prior studies with no new signals.
Key figures
- Drug Name
- firmonertinib
- Phase Of Trial
- Phase 3
- Trial name
- FURVENT (NCT05607550)
- Patients enrolled
- 398
- Bicr p value 240mg
- 0.0654
- Grade3 plus teae 240mg
- 52%
- Hazard ratio bicr 240mg
- 0.75 (0.55, 1.02)
- Confirmed orr 240mg bicr
- 60%
- Confirmed orr control bicr
- 33%
- Median pfs bicr 160mg months
- 8.4
- Median pfs bicr 240mg months
- 11
- Median pfs control bicr months
- 9.5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.